Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy

NCT04115956 is registered in ClinicalTrials.gov with Oncopeptides AB as lead sponsor.

NCT NCT04115956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04115956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients With AL Amyloidosis Following at Least One Prior Line of Therapy
Lead sponsor
Oncopeptides AB
Phase
Phase 1
Overall status
Terminated
Start date
August 6, 2020
Completion date
January 5, 2022
Enrollment
6 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis